Presence of more than one medical condition in a patient
POPULARITY
107 episodes with comorbidities
26 episodes with comorbidities
9 episodes with comorbidities
9 episodes with comorbidities
19 episodes with comorbidities
6 episodes with comorbidities
8 episodes with comorbidities
5 episodes with comorbidities
4 episodes with comorbidities
7 episodes with comorbidities
5 episodes with comorbidities
4 episodes with comorbidities
4 episodes with comorbidities
3 episodes with comorbidities
2 episodes with comorbidities
2 episodes with comorbidities
3 episodes with comorbidities
3 episodes with comorbidities
A Lasting Legacy: How Brain Donation Is Advancing Autism Research While organ donation can help save a life, brain donation can help save thousands. Specifically for autism, brain donations are helping researchers uncover the biological causes of the disorder to improve the quality of life for future generations. Our experts highlight the critical need for donation awareness and participation. Guests: Dr. David Amaral, scientific director, Autism BrainNet, Director of Research, UC Davis MIND Institute Kathy Stein, donor's loved one Fighting The Status Quo: The Rebels Who Changed Public Health Forever Prevention is built into so many aspects of our lives, from coffee cup lids to seatbelts. However, many of these life-saving innovations were historically met with extreme public and professional resistance. Our expert explores "preventioneers" – the people who defied taboo and skepticism to transform how we protect ourselves from disease and disaster. Guest: Dr. Barry Davis, professor emeritus, University of Texas School of Public Health, author, The Preventioneers Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
A Lasting Legacy: How Brain Donation Is Advancing Autism Research While organ donation can help save a life, brain donation can help save thousands. Specifically for autism, brain donations are helping researchers uncover the biological causes of the disorder to improve the quality of life for future generations. Our experts highlight the critical need for donation awareness and participation. Guests: Dr. David Amaral, scientific director, Autism BrainNet, Director of Research, UC Davis MIND Institute Kathy Stein, donor's loved one Host and Producer: Kristen Farrah Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What if every "non-compliant" patient was actually a signal that the system isn't working for them? In this episode, Jamie sits down with Jaclyn Taylor, Clinical Strategy Director at Your Health and a nurse practitioner who started her career as a home-based provider in 2020 — thrown straight into the fire of COVID, isolated patients, and a healthcare world rewriting itself in real time. What she saw inside patients' homes — medications scattered on tables, food insecurity, missing transportation — changed how she thinks about every chart she's ever read. You'll hear: Why a nurse-first pathway gives nurse practitioners a fundamentally different lens than a medical school pathway — and why patients feel it What working across home care, telehealth, trauma, and wellness teaches you about treating the whole human, not just the diagnosis Why trauma surgery turned Jacqueline into a believer in proactive, longitudinal care — and what gets missed when we only meet patients after something has already gone wrong The two words she uses to describe what's most broken in traditional healthcare: fragmentation and misalignment How empathy stops being a poster and starts being operational — built into the design of care itself If you've ever felt invisible inside the healthcare system, or if you're the one trying to fix it, this conversation reframes the whole game. Press play. www.YourHealth.Org
In this episode of Genetics in Your World, GSA Early Career Scientists Multimedia Subcommittee member Luke Arnce interviews Caitlin Peaslee of the Center for Embryonic Cell and Gene Therapy at Oregon Health and Science University about her research. Read her paper titled, "Mapping whole-organism genetic comorbidities across model species using unified ontologies," published in the April 2026 issue of GENETICS: https://doi.org/10.1093/genetics/iyag038 This study developed a cross-species computational framework, CoMo DBM, to analyze 204 mouse genes that caused non-obstructive azoospermia and mapped their phenotype associations across human, zebrafish, fruit fly, and roundworm databases. Music: Loopster Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 License, http://creativecommons.org/licenses/by/3.0/#GeneEditing #cancer #GeneOntology Hosted on Acast. See acast.com/privacy for more information.
Beyond the NICU: How Small Moments Shape a Developing BrainHow early experiences and neuroprotective care shape brain development and long-term outcomesWhat happens in the NICU does not end at discharge. In this episode, we take a deeper look at the lasting impact of NICU care and how early experiences shape a child's brain development and long-term outcomes. While many are familiar with the major complications of prematurity, we explore the often less visible—and frequently underestimated—effects sometimes referred to as “minor" or co- morbidities, and why there is nothing minor about their impact.We discuss how the premature brain is still developing, how stress and the NICU environment influence that development, and what happens when the stress response system develops under stress. More importantly, we walk through tangible, practical ways—core measures drawn from established models and frameworks—that support neuroprotective, family-centered, and developmentally supportive care in the NICU.This episode is for both NICU parents and clinicians. If you are a current NICU parent, you'll learn ways you can actively support your baby and feel more confident in your role. If your child is a NICU graduate, this episode may help explain some of the experiences and challenges you've seen—and remind you that you are not alone. And for clinicians, this is a powerful reminder of the impact you have every single day, and how small, intentional choices can shape the trajectory of a child's life.Because NICU care is not just about survival. It's about how we help these children grow, develop, and thrive long after they go home.Dr. Brown's Medical: https://www.drbrownsmedical.com The Infant-Driven Feeding™ (IDF) Program: https://www.infantdrivenfeeding.com/ Our NICU Roadmap: A Comprehensive NICU Journal: https://empoweringnicuparents.com/nicujournal/ NICU Mama Hats: https://empoweringnicuparents.com/hats/ NICU Milestone Cards: https://empoweringnicuparents.com/nicuproducts/ Newborn Holiday Cards: https://empoweringnicuparents.com/shop/ Empowering NICU Parents Show Notes: https://empoweringnicuparents.com/shownotes/ Episode 80 Show Notes: https://empoweringnicuparents.com/episode80 Empowering NICU Parents Instagram: https://www.instagram.com/empoweringnicuparents/ Empowering NICU Parents FB Group: https://www.facebook.com/groups/empoweringnicuparents Pinterest Page: https://pin.it/36MJjmHThank you for listening to the Empowering NICU Parents Podcast. Be sure to subscribe and leave us a review—it helps other families find us. We're grateful to be part of this incredible community. Visit www.empoweringnicuparents.com for resources and support.
Dr. Eduardo Butelman (Icahn School of Medicine at Mount Sinai, New York) joins AJP Audio to discuss the varying incidence of psychiatric comorbidities across patients diagnosed with substance use disorders. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin joins the podcast to discuss the rest of the May issue, which includes a discussion on the future of the DSM. 00:53 Butelman interview 02:23 Mechanisms of difference between males and females 04:04 Patterns of response between males and females in substance use disorders 05:54 Implications for research into sex-based differences 07:33 Racial and ethnic variations in findings 09:30 Limitations 10:46 Immediate clinical implications? 12:09 Further research 13:18 Kalin interview 13:38 Butelman et al. 17:11 Hinojosa et al. 22:49 van Rooij et al. 26:06 The future of DSM Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org
Daniel Eisen, MD, FAAD and Martina J Porter, MD, FAAD interviewed by Olayemi Sokumbi, MD, FAAD
Avoidant/Restrictive Food Intake Disorder (ARFID) is an eating disorder diagnosis characterized by a persistent restriction or avoidance of food intake that results in clinically significant consequences (medical, nutritional, and/or psychosocial), but without the weight- and shape-driven psychopathology typical of anorexia nervosa and bulimia nervosa. In this episode, Megan Hellner and Katherine Hill outline how ARFID presents across the lifespan, why it is frequently missed in routine healthcare, and what an evidence-informed assessment and treatment pathway can look like in practice. A central theme is that ARFID is not synonymous with "picky eating" and not confined to any one body size. Patients may present at any point on the weight chart, including those who are weight-stable or in larger bodies, and the condition can begin in early childhood and persist into adulthood. The episode also highlights ARFID in athletes and physically active people, where restricted dietary variety and/or low intake can contribute to low energy availability and RED-S-like presentations, sometimes without an obvious intent to lose weight. Timestamps [03:48] Interview start [06:23] What is ARFID? DSM-5 definition vs "picky eating" [09:36] Clinical red flags: when restriction becomes a disorder [11:37] ARFID isn't always underweight: missed cases & diagnostic pitfalls [16:46] ARFID presentation profiles: low interest, sensory sensitivity, fear [18:59] Comorbidities & nutrition consequences [25:16] Evidence-based ARFID treatment [29:16] How to expand foods without pressure [32:28] Weight restoration, stabilization, and long-term maintenance [35:44] What research still needs [38:16] Differential diagnosis & referral Links/Resources Go to episode page (with links to papers and ARFID resources) Subscribe to Sigma Nutrition Premium Join the Sigma email newsletter for free Enroll in the next cohort of our Applied Nutrition Literacy course
It is increasingly understood that our brain health is dependent on our having healthy nutrient levels. But how do nutrients actually impact our neurotransmitters.We might assume that certain nutrient levels would cause certain symptoms or conditions. Instead, what we find are biotypes - one condition is often associated with a small handful of imbalances. For example, the biotypes of depression from the Walsh Research Institute, included undermethylation, overmethylation, pyrrole disorder, copper overload and metal toxicity. And reversely, one nutrient imbalance can contribute to a range of brain symptoms. Copper overload, for example, can be a factor in ADHD for one person, but for another contribute to panic or insomnia and still another rage or tantrums. There are some conditions, however, that have a very strong associations with specific nutrient imbalances. In this newsletter, I will address:* 5 Ways Nutrients Impact Neurotransmitter Functioning* Psychiatric Conditions That Can Almost Predict a Specific Nutrient ImbalanceThe data comes from the Walsh Research Institute. Nutrient Imbalances Can Be Due to Too Much or Too LittleI use the term nutrient imbalances, because it's not just about deficiencies of certain nutrients. Specific nutrient overloads can impact brain health as well. This biochemical diversity means we don't all have the same needs when it comes to diet and supplementation. Some of us, for example, can benefit from folate, but for others with excess folate, supplementation could worsen depression and anxiety. Those with copper overload can similarly have worsening of symptoms with copper supplementation, while others will have a need for copper.What Causes Nutrient ImbalancesWhile it might seem that this is all about our intake of nutrients, we can come by these imbalances genetically. We can also acquire deficiencies and even overloads through high oxidative stress. This is when our body (including our brain) is dealing with too many insults, resulting in a depletion of our inherent antioxidants leaving us vulnerable to DNA and thus cell damage, inflammation and their consequences). Copper zinc imbalances and elevated pyrroles, which results in relatively low zinc and B6, are signs of oxidative stress. Often an imbalance appears to have multiple causes. For example a woman with high copper causing high anxiety, could have a family history of high copper conditions (post partum depression, ADHD, angry outbursts) and thus have a likely genetic vulnerability. She may also, be taking a multivitamin with copper, eating a lot of chocolate (high in copper) dealing with high oxidative stress and not the least, be on an oral contraceptive (added estrogen can make copper go up).5 Ways Nutrients Can Impact Neurotransmitter FunctioningNutrients often function as co-factors, helping certain enzymes do their job. Specific nutrients are needed: * For production of neurotransmitters. Vitamin B6, for example is needed to make serotonin, dopamine and GABA. B6 can be low in pyrrole disorder and thus contribute to a range of symptoms.* To convert one neurotransmitter to another. Copper is needed to turn dopamine into norepinephrine (think adrenaline). If we are high in copper, we could have relatively low dopamine and high adrenaline states, which is what is seen in ADHD.* To support enzymes involved in the breakdown of neurotransmitters. For example MAOA is an enzyme that needs Vitamin B2 to do its job breaking down serotonin, dopamine and norepinephrine. If these aren't broken down, there could be problems with activation and anxiety.* To help receptors do their job. Receptors are what neurotransmitters bind to, resulting in a impulse being sent down the nerve cell. Zinc and magnesium help regulate the NMDA receptor. If not well regulated, there can be high activity, which can look like thoughts getting stuck - ruminations, obsessions in OCD, cravings in addiction, and even delusions in psychosis.* Regulate the expression of genes for serotonin reuptake receptors. Folate causes an increase in the expression of these genes (and thus production of these receptors). This results in more serotonin being picked up and less available between nerve cells. This could be a problem for someone who already has low serotonin symptoms. SAMe, on the other hand, does the opposite and it can function like an SSRI.Why One Diagnosis Isn't Always Associated With One Imbalance* Psychiatric conditions appear to have various causes. If someone comes to me with a diagnosis of depression, for example, that only tells me what type of symptoms they likely have. It doesn't tell me if those symptoms are related to high copper, a methylation imbalance, elevated pyrroles, candida, a misaligned upper cervical spine , mast cell activation, mold toxicity, metal toxicity, hormone imbalances or a combination of any of these…….or something else.* More often multiple factors appear to be aligning. It is not uncommon, for example, to have candida or mold causing high pyrroles causing low zinc, leading to high copper, and as an aside also be undermethylated.* One “root cause” can contribute to a range of conditions and symptoms. Some people with high copper are diagnosed with depression or anxiety and others with ADHD. Some people who are undermethylated have OCD, others depression and still other schizophrenia. Very often, people will be have multiple diagnoses fitting with an imbalance. “Comorbidities” in psychiatry are the norm, rather than the exception.Despite all of this, there are certain nutrient imbalances that occur so commonly in certain psychiatric conditions that they can almost be predicted . Data From Walsh Research InstituteSimply knowing someone has a mental health condition makes it more likely that they will have a methylation imbalance - more often undermethylation.The Walsh Research Institute has looked at the methylation status of 30,000 over 40 year and found that 70% of those with mental illness exhibit a methylation imbalance (undermethylation and overmethylation). This is relative to the general population, in which 30% had a methylation imbalance.Other Data From the Walsh Research Institute:* History of Postpartum Depression - 95% have copper overload* ADHD - 68% have a copper zinc imbalance* Autism Spectrum Disorder - 98% undermethylation, 98% low zinc* Antisocial Personality Disorder - 95% undermethylation, 95% pyrrole disorder, 95% low zinc* Oppositional Defiant Disorder - 85% undermethylation* Schizoaffective Disorder - 90% undermethylation* Anorexia - 82% undermethylation* Schizophrenia - 70% undermethylation* Violent behavior - 78% high copperEvaluation & Labs Are Still ImportantNone of these are 100%. And, again, there is rarely one contributing factor, so a comprehensive evaluation and lab testing are still important. Even if I am fairly confident that someone is low in zinc, I don't recommend starting zinc without checking zinc and copper levels. Starting zinc too rapidly can mobilize high copper and worsen symptoms. If copper is low, zinc can cause a further decrease.Also, there are occasions when it can be difficult to address an imbalance, without addressing another contributing issue first. For example, I see some patients who are unable to tolerate treatment of undermethylation until they begin treatment for candida or mold.There is always so much more data to share, when it comes to the Walsh Research Institute. I look forward to discussing biotypes of depression, ADHD and schizophrenia in a future episode.As always, I welcome your comments and questions.Until next time,CourtneyTo learn more about my discovery calls, non-patient consultations, and treatment practice, visit:CourtneySnyderMD.comMedical Disclaimer:This newsletter is for educational purposes and not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment for either yourself or others, including but not limited to patients that you are treating (if you are a practitioner). Consult your physician for any medical issues that you may be having. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit courtneysnydermd.substack.com/subscribe
Eileen and Gittel talk about why they're passionate about leading support spaces, what those groups are really like (spoiler: welcoming, not intimidating), and how connection can make a huge difference. You'll also hear gentle, practical advice for those early days like pacing yourself, adapting as you go, and redefining what it means to thrive. It's a comforting reminder that even with chronic illness, you can still build a full, meaningful life and you don't have to figure it out alone. And if you'd like to join one of the latest Rheum to THRIVE groups, you can do so here. Episode at a glance: 00:00 Meet the New Facilitators 01:13 Diagnoses and Comorbidities 04:35 Why Eileen Facilitates 08:06 Why Gittel (GT) Facilitates 12:09 Why Support Groups Matter 15:27 Program Structure Highlights 22:43 GT's Teaching Style 23:32 Creating Safe Space 24:28 Alumni Group Exploration 25:46 Eileen's Facilitation Style 33:42 Common Support Group Worries Addressed 37:48 Importance of Diversity In Groups 41:41 Reflections on Thriving With Arthritis Medical disclaimer: All content found on Arthritis Life public channels was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Episode Sponsors Rheum to THRIVE, an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. See all the details and join the program or waitlist now! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Podcast Episode 1: A Pragmatic Overview of Heart Failure in Patients with Diabetes for Endocrinologists, Primary Care Physicians and Noncardiologist Clinicians This podcast is published open access in Diabetes Therapy and is fully citeable. You can access the original published podcast article through the Diabetes Therapy website and by using this link: https://link.springer.com/article/10.1007/s13300-026-01855-7. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
What if the healthcare system your loved one relies on doesn't even know they need help until it's too late — and what would it look like if it did? In this Q1 2026 episode, Jamie Preston sits down with Matt Staub, CEO of Your Health, for a candid and wide-ranging look at how one of the country's largest home-based care providers is navigating the evolving landscape of value-based care, population health, and the human experience at the center of it all. Matt brings his characteristic clarity and heart to a conversation that is equal parts strategy, story, and honest reckoning with what the system still gets wrong. Key topics covered: Why 11% of patients account for 67% of all healthcare spending — and why most of them don't know they're in an ACO The evolution of value-based care: from quality-over-cost to outcomes + patient experience over total costs How Your Health is becoming proactive — not reactive — about falls, readmissions, and high-needs patients The quiet crisis of patient trust: down from 71% in 2020 to just 33% today, and what the correlation means for hospitalizations Real stories: a 79-year-old patient who went from barely existing to living fully — and Matt's own mom, who hasn't fallen since leaving the hospital after her stroke If you work in healthcare, advocate for someone in the system, or simply believe that better is possible — this episode will change the way you see what care can be.
[你的骨盆、你的情緒容器：在「創傷友善」中，重新掌握骨盆的自由]
This podcast script debunks common misconceptions surrounding Nonverbal Learning Disorder (NLD), emphasizing that co-occurring conditions like ADHD, anxiety, and sensory sensitivities are the rule rather than the exception. Rather than viewing these traits as childhood-only deficits or a lack of intelligence, the script highlights that understanding the scientific facts empowers neurodivergent adults to build resilience and sharp problem-solving skills. Ultimately, embracing one's complete neurodivergent profile helps dismantle internalized blame, paving the way for strong self-advocacy and personalized systems of support.https://linktr.ee/JenniferPTTS?utm_source=linktree_profile_shareArticles Cited in This EpisodeMasking in Neurodivergent Adults: Psychological Costs and Coping Strategies – Autism Research, 2022https://onlinelibrary.wiley.com/doi/10.1002/aur.2478Neurodiversity: Definitions, Prevalence, and Clinical Implications – MDPI Social Sciences, 2023https://www.mdpi.com/2428-6200/3/4/91Emotional Awareness and Cognitive Strengths in NLD – Frontiers in Psychology, 2023https://www.frontiersin.org/articles/10.3389/fpsyg.2023.12345/fullSensory Hypersensitivity and Migraine: Mechanisms and Clinical Implications – ScienceDirect, 2020https://www.sciencedirect.com/science/article/pii/S003537872030463X
In this revisited episode, Dr. Robyn Thom discusses autism spectrum disorder (ASD) and the psychiatric comorbidities that frequently accompany it. She reviews how ASD is diagnosed, the core domains of social communication differences and restricted or repetitive behaviors, and why treatment often focuses on co-occurring conditions such as anxiety, ADHD, sleep disorders, and agitation. Dr. Thom also shares practical strategies for evaluating agitation, distinguishing overlapping symptoms, and selecting behavioral and pharmacologic interventions to support patients with ASD across the lifespan. Robyn Thom, MD, is an Assistant Professor of Psychiatry at Harvard Medical School and a staff psychiatrist at the Massachusetts General Hospital Lurie Center for Autism. She specializes in treating children and adults with autism spectrum disorder and other neurodevelopmental conditions, with clinical and research interests in psychiatric comorbidities, anxiety, and mood disorders. Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26 Register today at nei.global/spring Never miss an episode!
Episode 216: Fibromyalgia Overview Reitta Wyllie and Tejasvi Ayaggari (medical students) discuss with Dr. Arreaza the presentation, diagnosis and management of fibromyalgia, a commonly unrecognized disease that may impact patient's quality of life if left untreated. Written by Reitta Nash, MSIV, American University of the Caribbean. Additional commentary provided by Dr. Tejasvi Ayyagari. Edits and comments by Hector Arreaza, MD. You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice. Introduction Fibromyalgia is a chronic pain condition that affects millions of people worldwide, yet it remains one of the most misunderstood disorders in medicine. Patients often experience widespread pain, fatigue, sleep disturbances, cognitive difficulties, and a host of other symptoms that significantly impact daily functioning and quality of life. TJ: It's common, but I feel it is mostly misunderstood and sometimes goes undiagnosed. Reitta: Yes, despite its prevalence, fibromyalgia has historically been met with skepticism, delayed diagnosis, and stigma. Today, we'll break down what fibromyalgia is, what we know about its underlying mechanisms, how it's diagnosed, and how it's managed using evidence-based approaches. What is fibromyalgia? Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, accompanied by symptoms such as fatigue, non-restorative sleep, cognitive dysfunction often referred to as “fibro/brain fog,” and mood disturbances. TJ: Unlike inflammatory or autoimmune diseases, fibromyalgia does not cause structural damage to joints or muscles, nor does it produce objective findings on imaging or routine laboratory testing. Instead, it is considered a centralized pain disorder, meaning pain processing within the central nervous system is altered. Arreaza: Many years ago, I had a patient who had fibromyalgia in Germany. He shared how hard it was for him to get diagnosed and treated because many countries fail to recognize fibromyalgia as a disease. However, Germany is not one of them. The German Association of the Medical Scientific Societies (AWMF) has established specific diagnostic criteria for fibromyalgia syndrome (FMS). Also, the World Health Organization recognizes fibromyalgia as a chronic condition, and it is included in the International Classification of Diseases 10th edition (ICD-10). Reitta: The American College of Rheumatology (ACR) recognizes fibromyalgia as a distinct clinical diagnosis, affecting approximately 2–4% of the population, with a higher prevalence in women, though it can affect individuals of any sex or age. Historical Perspective Fibromyalgia was once referred to by terms such as fibrositis, a name that implied inflammation of connective tissue. However, as research failed to demonstrate inflammatory changes, the terminology evolved. In 1990, the American College of Rheumatology introduced the first formal diagnostic criteria, which focused heavily on tender point examination. Over time, these criteria were revised as understanding of the condition improved. Modern diagnostic criteria no longer rely on tender points and instead emphasize symptom severity and widespread pain distribution, reflecting a more patient-centered and clinically practical approach. What causes fibromyalgia? The exact cause of fibromyalgia is not fully understood, but current evidence supports a multifactorial, neurobiological model. The American Academy of Family Physicians identifies a spectrum of chronic overlapping pain conditions that frequently coexist with fibromyalgia, including IBS, TMJ pain, vulvodynia, Chronic fatigue syndrome, interstitial cystitis, endometriosis, chronic tension headaches, migraine, and chronic low back pain. These functional somatic conditions may represent a single disorder manifesting as pain in different body regions at different times over the life span. _____________________ References: Aaron RV, Ravyts SG, Carnahan ND,et al. Prevalence of depression and anxiety among adults with chronic pain: a systematic review and metaanalysis‑analysis. JAMA Netw Open. 2025;8(3):e250268. doi:10.1001/jamanetworkopen.2025.0268. PMID: 40053352. Bradley LA. Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatry. 2008;69(Suppl 2):6‑14. PMID: 19962493. doi:10.4088/JCP.v69s02102. Häuser W, Ablin J, Fitzcharles MA, et al. Fibromyalgia. Am Fam Physician. 2023;107(2):158‑166. Häuser W, Fitzcharles MA. Facts and myths pertaining to fibromyalgia. Nat Rev Rheumatol. 2018;14(9):525‑535. PMID: 38607678; doi:10.1038/s41584‑018‑0084‑4. Kleykamp BA, Ferguson MC, McNicol E, et al.The prevalence of psychiatric and chronic pain comorbidities in fibromyalgia: An ACTION systematic review. Semin Arthritis Rheum. 2021;51(1):166‑174. PMID: 33383293. doi:10.1016/j.semarthrit.2020.10.006. Magen E, Tolkin L, Aamar S, et al.Endocrine comorbidities in fibromyalgia. Clin Endocrinol (Oxf). 2025;[Epub ahead of print]. doi:10.xxxx/clinend.2025.xxxxx. Mohabbat AB, Wilkinson JM. Central sensitization: When it is not “all in your head.” Am Fam Physician. 2023;107(1):92‑96. Moscati A, Faucon AB, ArnaizYépez‑Yépez C, et al.Life is pain: Fibromyalgia as a nexus of multiple liability distributions. Am J Med Genet B Neuropsychiatr Genet. 2023;192(2):134‑148. doi:10.1002/ajmg.b.32911. Rivera FA, Munipalli B, Allman ME, et al.A retrospective analysis of the prevalence and impact of associated comorbidities on fibromyalgia outcomes in a tertiary care center. Front Med (Lausanne). 2023;10:1184734. doi:10.3389/fmed.2023.1184734. Sleurs D, Tebeka S, Scognamiglio C, Dubertret C, Le Strat Y. Comorbidities of selfreported fibromyalgia in United States adults: A ‑reported fibromyalgia in United States adults: A crosssectional‑sectional study from the NESARC‑III. Eur J Pain. 2020;24(9):1687‑1698. doi:10.1002/ejp.1619. Winslow BT, Vandal C, Dang L. Fibromyalgia: Diagnosis and management. Am Fam Physician. 2023;107(2):158‑166. PMID: 36791450. Wolfe F, Clauw DJ, Fitzcharles MA, et al. Revisions to the American College of Rheumatology fibromyalgia diagnostic criteria. Arthritis Care Res (Hoboken). 2023;75(12):2029‑2039. PMID: 41097025. doi:10.1002/acr.24963. Wolfe F, Clauw DJ, Fitzcharles MA, et al.Revisions to the American College of Rheumatology fibromyalgia diagnostic criteria. Arthritis Care Res (Hoboken). 2023;75(12):2029‑2039. PMID: 41097025. doi:10.1002/acr.24963. Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.
Your Guide To Living With Adhd: Managing Daily Life, Healthcare, And Intimacy Living with ADHD often means struggling with essential executive functions like focus and organization. Because symptoms manifest differently in each person, many people lack the specific systems and structures needed to manage their unique challenges. Our guest offers advice on various coping strategies and what to do when those structures fail. Guest: Cate Osborn, online mental health advocate, co-author, The ADHD Field Guide for Adults Host: Elizabeth Westfield Producer: Kristen Farrah. From Doctor To Patient: Lessons In Self-Advocacy From A Physician Dr. Sylvia Owusu-Ansah's life took a turn when a routine medical screening became anything but. Despite her professional expertise, she still had to navigate the frightening transition from provider to patient. Owusu-Ansah explains how she's using her story to show others how to self-advocate when navigating the healthcare system. Guest: Dr. Sylvia Owusu-Ansah, pediatric emergency medicine physician, assistant professor of pediatrics and emergency medicine, University of Pittsburgh School of Medicine, cancer patient Host: Greg Johnson Producers: Kristen Farrah Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Your Guide To Living With Adhd: Managing Daily Life, Healthcare, And Intimacy Living with ADHD often means struggling with essential executive functions like focus and organization. Because symptoms manifest differently in each person, many people lack the specific systems and structures needed to manage their unique challenges. Our guest offers advice on various coping strategies and what to do when those structures fail. Guest: Cate Osborn, online mental health advocate, co-author, The ADHD Field Guide for Adults Host: Elizabeth Westfield Producer: Kristen Farrah Links for information: Osborn InstagramOsborn WebsiteADHD Book Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice. Guests: Hina Khan, MD Thoracic Oncologist Assistant Professor of Medicine Warren Alpert Medical School, Brown University Corey Langer, MD, FACP Director, Thoracic Oncology, Abramson Cancer Center Professor of Medicine , Perelman School of Medicine University of Pennsylvania
In this episode, we explore the treatment algorithm for adult ADHD with Dr. Oscar Bukstein from Harvard Medical School. Should you start with stimulants or non-stimulants when substance use disorder complicates the picture? Discover how comorbidities like depression and anxiety reshape your medication selection strategy for optimal patient outcomes. Faculty: Oscar G. Bukstein, M.D., M.P.H Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Mastering Adult ADHD: A Comprehensive Clinical Guide Treatment Algorithm for Adult ADHD
In this episode of BS Free MD, Walt Heyer shares his personal history, including childhood adversity, substance use, and the path that led him to medically transition and later reverse course. He argues that “affirmation-first” models in therapy and medicine often skip deeper assessment and fail to address root causes like abuse, PTSD, anxiety/depression, autism traits, or other psychological distress. Drs. May and Tim discuss how rapidly rising youth identification trends may be influenced by peer dynamics and online content, and they emphasize the need for careful evaluation, family involvement, and ethical guardrails—especially when irreversible medical decisions are involved. GET SOCIAL WITH US!
Psychogenic nonepileptic seizures (PNES) are common, often misunderstood, and increasingly encountered in pediatric emergency care. These events closely resemble epileptic seizures but arise from abnormal brain network functioning rather than epileptiform activity. In this episode of PEM Currents, we review the epidemiology, pathophysiology, and clinical features of PNES in children and adolescents, with a practical focus on Emergency Department recognition, diagnostic strategy, and management. Particular emphasis is placed on seizure semiology, avoiding iatrogenic harm, communicating the diagnosis compassionately, and understanding how early identification and referral to cognitive behavioral therapy can dramatically improve long-term outcomes. Learning Objectives Identify key epidemiologic trends, risk factors, and semiological features that help differentiate psychogenic nonepileptic seizures from epileptic seizures in pediatric patients presenting to the Emergency Department. Apply an evidence-based Emergency Department approach to the evaluation and initial management of suspected PNES, including strategies to avoid unnecessary escalation of care and medication exposure. Demonstrate effective, patient- and family-centered communication techniques for explaining the diagnosis of PNES and facilitating timely referral to appropriate outpatient therapy. References Sawchuk T, Buchhalter J, Senft B. Psychogenic Nonepileptic Seizures in Children-Prospective Validation of a Clinical Care Pathway & Risk Factors for Treatment Outcome. Epilepsy & Behavior. 2020;105:106971. (PMID: 32126506) Fredwall M, Terry D, Enciso L, et al. Outcomes of Children and Adolescents 1 Year After Being Seen in a Multidisciplinary Psychogenic Nonepileptic Seizures Clinic. Epilepsia. 2021;62(10):2528-2538. (PMID: 34339046) Sawchuk T, Buchhalter J. Psychogenic Nonepileptic Seizures in Children - Psychological Presentation, Treatment, and Short-Term Outcomes. Epilepsy & Behavior. 2015;52(Pt A):49-56. (PMID: 26409129) Labudda K, Frauenheim M, Miller I, et al. Outcome of CBT-based Multimodal Psychotherapy in Patients With Psychogenic Nonepileptic Seizures: A Prospective Naturalistic Study. Epilepsy & Behavior. 2020;106:107029. (PMID: 32213454) Transcript This transcript was generated using Descript automated transcription software and has been reviewed and edited for accuracy by the episode's author. Edits were limited to correcting names, titles, medical terminology, and transcription errors. The content reflects the original spoken audio and was not substantively altered. Welcome to PEM Currents: The Pediatric Emergency Medicine Podcast. As always, I'm your host, Brad Sobolewski, and today we are talking about psychogenic non-epileptic seizures, or PNES. Now, this is a diagnosis that often creates a lot of uncertainty in the Emergency Department. These episodes can be very scary for families and caregivers and schools. And if we mishandle the diagnosis, it can lead to unnecessary testing, medication exposure, ICU admissions, and long-term harm. This episode's gonna focus on how to recognize PNES in pediatric patients, how we make the diagnosis, what the evidence says about management and outcomes, and how what we do and what we say in the Emergency Department directly affects patients, families, and prognosis. Psychogenic non-epileptic seizures are paroxysmal events that resemble epileptic seizures but occur without epileptiform EEG activity. They're now best understood as a subtype of functional neurological symptom disorder, specifically functional or dissociative seizures. Historically, these events were commonly referred to as pseudo-seizures, and that term still comes up frequently in the ED, in documentation, and sometimes from families themselves. The problem is that pseudo implies false, fake, or voluntary, and that implication is incorrect and harmful. These episodes are real, involuntary, and distressing, even though they're not epileptic. Preferred terminology includes psychogenic non-epileptic seizures, or PNES, functional seizures, or dissociative seizures. And PNES is not a diagnosis of exclusion, and it does not require identification of psychological trauma or psychiatric disease. The diagnosis is based on positive clinical features, ideally supported by video-EEG, and management begins with clear, compassionate communication. The overall incidence of PNES shows a clear increase over time, particularly from the late 1990s through the mid-2010s. This probably reflects improved recognition and access to diagnostic services, though a true increase in occurrence can't be excluded. Comorbidity with epilepsy is really common and clinically important. Fourteen to forty-six percent of pediatric patients with PNES also have epilepsy, which frequently complicates diagnosis and contributes to diagnostic delay. Teenagers account for the highest proportion of patients with PNES, especially 15- to 19-year-olds. Surprisingly, kids under six are about one fourth of all cases, so it's not just teenagers. We often make the diagnosis of PNES in epilepsy monitoring units. So among children undergoing video-EEG, about 15 to 19 percent may ultimately be diagnosed with PNES. And paroxysmal non-epileptic events in tertiary epilepsy monitoring units account for about 15 percent of all monitored patients. Okay, but what is PNES? Well, it's best understood as a disorder of abnormal brain network functioning. It's not structural disease. The core mechanisms at play include altered attention and expectation, impaired integration of motor control and awareness, and dissociation during events. So the patients are not necessarily aware that this is happening. Psychological and psychosocial features are common but not required for diagnosis and may be less prevalent in pediatric populations as compared with adults. So PNES is a brain-based disorder. It's not conscious behavior, it's not malingering, and it's not under voluntary control. Children and adolescents with PNES have much higher rates of psychiatric comorbidities and psychosocial stressors compared to both healthy controls and children with epilepsy alone. Psychiatric disorders are present in about 40 percent of pediatric PNES patients, both before and after the diagnosis. Anxiety is seen in 58 percent, depression in 31 percent, and ADHD in 35 percent. Compared to kids with epilepsy, the risk of psychiatric disorders in PNES is nearly double. Compared to healthy controls, it is up to eight times higher. And there's a distinct somatopsychiatric profile that strongly predicts diagnosis of PNES. This includes multiple medical complaints, psychiatric symptoms, high anxiety sensitivity, and solitary emotional coping. This profile, if you've got all four of them, carries an odds ratio of 15 for PNES. Comorbid epilepsy occurs in 14 to 23 percent of pediatric PNES cases, and it's associated with intellectual disability and prolonged diagnostic delay. And finally, across all demographic strata, anxiety is the most consistent predictor of PNES. Making the diagnosis is really hard. It really depends on a careful history and detailed analysis of the events. There's no single feature that helps us make the diagnosis. So some of the features of the spells or events that have high specificity for PNES include long duration, so typically greater than three minutes, fluctuating or asynchronous limb movements, pelvic thrusting or side-to-side head movements, ictal eye closure, often with resisted eyelid opening, ictal crying or vocalization, recall of ictal events, and rare association with injury. Younger children often present with unresponsiveness. Adolescents more commonly demonstrate prominent motor symptoms. In pediatric cohorts, we most frequently see rhythmic motor activity in about 27 percent, and complex motor movements and dialeptic events in approximately 18 percent each. Features that argue against PNES include sustained cyanosis with hypoxia, true lateral tongue biting, stereotyped events that are identical each time, clear postictal confusion or lethargy, and obviously epileptic EEG changes during the events themselves. Now there are some additional historical and contextual clues that can help us make the diagnosis as well. If the events occur in the presence of others, if they occur during stressful situations, if there are psychosocial stressors or trauma history, a lack of response to antiepileptic drugs, or the absence of postictal confusion, this may suggest PNES. Lower socioeconomic status, Medicaid insurance, homelessness, and substance use are also associated with PNES risk. While some of these features increase suspicion, again, video-EEG remains the diagnostic gold standard. We do not have video-EEG in the ED. But during monitoring, typical events are ideally captured and epileptiform activity is not seen on the EEG recording. Video-EEG is not feasible for every single diagnosis. You can make a probable PNES diagnosis with a very accurate clinical history, a vivid description of the signs and appearance of the events, and reassuring interictal EEG findings. Normal labs and normal imaging do not make the diagnosis. Psychiatric comorbidities are not required. The diagnosis, again, rests on positive clinical features. If the patient can't be placed on video-EEG in a monitoring unit, and if they have an EEG in between events and it's normal, that can be supportive as well. So what if you have a patient with PNES in the Emergency Department? Step one, stabilize airway, breathing, circulation. Take care of the patient in front of you and keep them safe. Use seizure pads and precautions and keep them from falling off the bed or accidentally injuring themselves. A family member or another team member can help with this. Avoid reflexively escalating. If you are witnessing a PNES event in front of you, and if they're protecting their airway, oxygenating, and hemodynamically stable, avoid repeated benzodiazepines. Avoid intubating them unless clearly indicated, and avoid reflexively loading them with antiseizure medications such as levetiracetam or valproic acid. Take a focused history. You've gotta find out if they have a prior epilepsy diagnosis. Have they had EEGs before? What triggered today's event? Do they have a psychiatric history? Does the patient have school stressors or family conflict? And then is there any recent illness or injury? Only order labs and imaging when clinically indicated. EEG is not widely available in the Emergency Department. We definitely shouldn't say things like, “this isn't a real seizure,” or use outdated terms like pseudo-seizure. Don't say it's all psychological, and please do not imply that the patient is faking. If you see a patient and you think it's PNES, you're smart, you're probably right, but don't promise diagnostic certainty at first presentation. Remember, a sizable proportion of these patients actually do have epilepsy, and referring them to neurology and getting definitive testing can really help clarify the diagnosis. Communication errors, especially early on, worsen outcomes. One of the most difficult things is actually explaining what's going on to families and caregivers. So here's a suggestion. You could say something like: “What your child is experiencing looks like a seizure, but it's not caused by abnormal electrical activity in the brain. Instead, it's what we call a functional seizure, where the brain temporarily loses control of movement and awareness. These episodes are real and involuntary. The good news is that this condition is treatable, especially when we address it early.” The core treatment of PNES is CBT-based psychotherapy, or cognitive behavioral therapy. That's the standard of care. Typical treatment involves 12 to 14 sessions focused on identifying triggers, modifying maladaptive cognitions, and building coping strategies. Almost two thirds of patients achieve full remission with treatment. About a quarter achieve partial remission. Combined improvement rates reach up to 90 percent at 12 months. Additional issues that neurologists, psychologists, and psychiatrists often face include safe tapering of antiseizure medications when epilepsy has been excluded, treatment of comorbid anxiety or depression, coordinating care between neurology and mental health professionals, and providing education for schools on event management. Schools often witness these events and call prehospital professionals who want to keep patients safe. Benzodiazepines are sometimes given, exposing patients to additional risk. This requires health system-level and outpatient collaboration. Overall, early diagnosis and treatment of PNES is critical. Connection to counseling within one month of diagnosis is the strongest predictor of remission. PNES duration longer than 12 months before treatment significantly reduces the likelihood of remission. Video-EEG confirmation alone does not predict positive outcomes. Not every patient needs admission to a video-EEG unit. Quality of communication and speed of treatment, especially CBT-based therapy, matter the most. Overall, the prognosis for most patients with PNES is actually quite favorable. There are sustained reductions in events along with improvements in mental health comorbidities. Quality of life and psychosocial functioning improve, and patients use healthcare services less frequently. So here are some take-home points about psychogenic non-epileptic seizures, or PNES. Pseudo-seizure and similar terms are outdated and misleading. Do not use them. PNES are real, involuntary, brain-based events. Diagnosis relies on positive clinical features, what the events look like and when they happen, not normal lab tests or CT scans. Early recognition and diagnosis, and rapid referral to cognitive behavioral therapy, change patients' lives. If you suspect PNES, get neurology and mental health professionals involved as soon as possible. Alright, that's all I've got for this episode. I hope you found it educational. Having seen these events many times over the years, I recognize how scary they can be for families, schools, and our prehospital colleagues. It's up to us to think in advance about how we're going to talk to patients and families and develop strategies to help children who are suffering from PNES events. If you've got feedback about this episode, send it my way. Likewise, like, rate, and review, as my teenagers would say, and share this episode with a colleague if you think it would be beneficial. For PEM Currents: The Pediatric Emergency Medicine Podcast, this has been Brad Sobolewski. See you next time.
In this episode of the MyHeart.net podcast, Dr. Alain Bouchard discusses the interplay between Heart Failure with Preserved Ejection Fraction, or HFpEF, and obesity with Dr. Michelle Kittleson, Director of Heart Failure Research at the Smidt Heart Institute at Cedars-Sinai.Learn more about the diagnosis, challenges, and management of this condition by exploring our article, Managing Obesity in Heart Failure with Preserved Ejection Fraction (HFpEF).About the TeamDr. Alain Bouchard is a clinical cardiologist at Cardiology Specialists of Birmingham, AL. He is a native of Quebec, Canada and trained in Internal Medicine at McGill University in Montreal. He continued as a Research Fellow at the Montreal Heart Institute. He did a clinical cardiology fellowship at the University of California in San Francisco. He joined the faculty at the University of Alabama Birmingham from 1986 to 1990. He worked at CardiologyPC and Baptist Medical Center at Princeton from 1990-2019. He is now part of the Cardiology Specialists of Birmingham at UAB Medicine.Dr. Philip Johnson is originally from Selma, AL. Philip began his studies at Vanderbilt University in Nashville, TN, where he double majored in Biomedical and Electrical Engineering. After a year in the “real world” working for his father as a machine design engineer, he went to graduate school at UAB in Birmingham, AL, where he completed a Masters and PhD in Biomedical Engineering before becoming a research assistant professor in Biomedical Engineering. After a short stint in academics, he continued his education at UAB in Medical School, Internal Medicine Residency, and is currently a cardiology fellow in training with a special interest in cardiac electrophysiology.Medical DisclaimerThe contents of the MyHeart.net podcast, including as textual content, graphical content, images, and any other content contained in the Podcast (“Content”) are purely for informational purposes. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or heard on the Podcast!If you think you may have a medical emergency, call your doctor or 911 immediately. MyHeart.net does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Podcast. Reliance on any information provided by MyHeart.net, MyHeart.net employees, others appearing on the Podcast at the invitation of MyHeart.net, or other visitors to the Podcast is solely at your own risk.The Podcast and the Content are provided on an “as is” basis.
How can we optimize ART in people living with HIV while addressing comorbidities and minimizing toxicity? Credit available for this activity expires: 01/15/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/balancing-art-and-comorbidities-aging-people-living-hiv-2026a1000127?ecd=bdc_podcast_libsyn_mscpedu
Panelists: Vanessa Hill, NP-C Lindsay Tom, PA-C Barb Slusher Jack Cush, MD
Empower your conversations with patients living with narcolepsy. Learn best clinical practices for identifying, discussing, and managing cardiovascular comorbidities to improve long-term outcomes. Credit available for this activity expires: 12/04/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/expert-conversations-narcolepsy-improving-sleep-quality-2025a1000xq4?ecd=bdc_podcast_libsyn_mscpedu
For those asking, here is the overdue podcast release of my debate with Mark Cuban on Covid mandates. We've been aggressively prioritizing promotion of your YouTube channel this past month — something we haven't done before — and we unfortunately got behind on posting on podcast platforms. Moving forward, this will not be an issue. Enjoy the debate if you'd like to listen while driving or doing other activities! SummaryIn this conversation, Mark and I engage in a fiery debate about the COVID-19 pandemic, vaccine mandates, and the implications of free speech in academia. We explore the complexities of public health decisions, the perceived biases in academic discourse, and the evolving understanding of vaccine efficacy and safety. Mark defends the necessity of vaccine mandates for protecting public health, while I raise concerns about the adverse effects and the risk-benefit analysis for young people.—Spotify linkApple link(also available on Overcast and other platforms)—Chapters00:00 Diversity in Hiring: Merit vs. Representation21:11 The Efficacy of Vaccines and Community Health27:10 Vaccine Policies Across Europe33:19 Community Responsibility and Vaccination39:12 Myocarditis Risks and Vaccine Decisions47:06 Accountability for Vaccine Mandates52:40 Understanding Myocarditis Risks: Infection vs. Vaccine58:42 The Role of Comorbidities in COVID Outcomes01:04:01 Analyzing Risk: Vaccination vs. Natural Infection01:09:52 Community Benefit vs. Individual Risk in Vaccination—The Illusion of Consensus is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This episod is brought to you by Cured Nutrition, Caldera Lab and Joi & Blokes. Dr. Jessica Shepherd—OB/GYN, clinical advisor for P-Volv, and author of Generation M—breaks down everything women need to know about perimenopause, menopause, and longevity. She explains why mindset is the foundation of midlife health, how declining estrogen affects every organ system, why only 8% of symptomatic women ever receive a diagnosis, and how common comorbidities rise 45% or more between ages 40–59. Dr. Shepherd shares science-backed strategies for navigating symptoms, improving metabolic and mitochondrial health, understanding the truth about hormone therapy after the flawed WHI study (which led to an 82% decline in prescriptions), and using exercise, protein, and muscle-building to protect cognition, heart health, and overall vitality. Whether you're a woman entering midlife—or a partner wanting to better support her—this conversation is a masterclass in women's health, empowerment, and aging well. Follow Jessica @jessicashepherdmd Follow Chase @chase_chewning ----- 00:01 - Intro & shocking stats: women live longer but spend more years in poor health; HRT prescriptions dropped 82% after 2002 00:28 - Muscle as the organ of longevity; women lose 3–5% per decade, accelerated after menopause 01:18 - Why estrogen decline shifts the whole body; Dr. Shepherd introduces herself and her mission in women's health 02:15 - Redefining women's health & longevity; why women aren't thinking about longevity soon enough 04:23 – Mindset, habits, and community as the foundation of midlife health 07:13 - Barriers to staying well: socioeconomic factors, upbringing, access, and misconceptions about wellness 09:33 - Women's current wellness landscape; societal expectations, caregiving burden, and systemic gaps 12:46 – Major healthcare gaps: lack of research, exclusion of women from clinical studies until the '70s, and only 3% of VC health funding going to women 17:30 – Pharma eliminating women's health divisions; downstream effects on innovation and access 19:10 – Perimenopause 101: defining terms, symptoms vs. cycles, 34+ possible symptoms, and why diagnosis is trick 24:45 – The cardiovascular danger of estrogen decline; heart disease as the #1 killer of women 27:02 – Stress vs. perimenopause symptoms; mood disorders peak between 45–55 29:48 – How HRT has evolved in the last 10–20 years; symptom relief and longevity benefits 32:32 – Why only 5% of women are on hormone therapy today; misconceptions and new guidelines 34:20 – WHI study deep dive: media panic, misinterpretation, lack of statistical significance, and lasting fear 39:06 – Risk vs. benefit: how to think about HRT decisions with your provider 41:51 – Chase shares his TRT story; quality of life, fertility considerations, and hormone literacy 45:16 – Dr. Shepherd's personal hormone story: cognition issues, testosterone, and starting estrogen at 46 48:12 – Supplements Dr. Shepherd uses: Vitamin D, creatine, CoQ10, Urolithin A 50:10 – Muscle, mitochondrial health, sarcopenia & glucose control: why resistance training is non-negotiable 52:25 – Movement, neuroplasticity, balance & cognition: why staying active protects the aging brain 55:12 – How partners can best support women in perimenopause: emotional support & shared routines 57:52 – The science of emotional support: social connection decreases pain, inflammation, and improves outcomes 59:22 – Menopause explained: average age, symptom timeline, and the hidden cellular changes 01:02:39 – Nutrition, glucose control, protein needs, alcohol & sugar intake, and metabolic health 01:07:07 – Protein requirements (1.0–1.2g/kg), resistance training, and why women must build muscle 01:09:37 – U.S. data: 55%+ of women report symptoms; only 8% diagnosed; why doctors miss it 01:12:34 – Which providers are best for menopause care & what certifications to look for 01:15:31 – Comorbidities rise 45% between 40–59: hypertension, thyroid, arthritis, sleep disorders & estrogen's role 01:18:25 – Is biohacking menopause possible? Current limits + ovarian longevity research 01:22:24 – Exercise as the ultimate biohack; sustainable movement for aging wel 01:23:19 – Final Q: How Dr. Shepherd lives Ever Forward — flexibility, pause, and growth ----- Episode resources: 20% off DREAM gummies with code EVERFORWARD at CuredNutrition.com/everforward 50% off any product or diagnostic labs with code CHASE at JoiAndBlokes.com/chase 20% off any men's skincare product with code EVERFORWARD at CalderaLab.com Watch and subscribe on YouTube
Are you looking beyond the lung to provide holistic care for your patients with multimorbid chronic obstructive pulmonary disease (COPD)? Credit available for this activity expires: 11/26/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/coexisting-comorbidities-advancing-holistic-care-copd-2025a1000uiz?ecd=bdc_podcast_libsyn_mscpedu
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SMF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SMF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SMF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SMF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This week we answer a question from a 19 year old college student rooming with her boyfriend but needing to breakup with him, and a person with ADHD, ASD and OCD managing their symptoms and their childJoin our patreon!Listen ad-free, get the show a day early and enjoy the pre-show hang out on the same app you're using RIGHT NOW at www.Patreon.com/Therapy where you can also access our vast library of deep dives, interviews, skill shares, reviews and rants as well as our live discord chat!If you are an Apple user please rate us!If you are a Spotify user, please rate us!Submit a question to the show!Help us reach #1 on Goodpods!Interested in Nick's mental health approach to fitness? Check out www.MentalFitPersonalTraining.comCheck out Dr. Jim's book "Dadvice: 50 Fatherly Life Lessons" at www.DadviceBook.comGrab some swag at our store, www.PodTherapyBaitShop.comPlay Jim's Neurotic Bingo at home while you listen to the show, or don't, I'm not your supervisor.Submit questions to:www.PodTherapy.netPodTherapyGuys@gmail.comFollow us on Social Media:FacebookInstagramTwitterResources:Suicide Prevention Lifeline - 1-800-273-8255.Veterans Crisis Line - 1-800-273-8255.Substance Abuse & Mental Health Services Administration (SAMHSA) National Helpline - (1-800-662-HELP (4357)OK2Talk Helpline Teen Helpline - 1 (800) 273-TALKU.S. Mental Health Resources Hotline - 211
Living with constant congestion, facial pressure, or a loss of smell can make daily life exhausting. For many people, these symptoms are more than just allergies or a lingering cold. They may be signs of chronic rhinosinusitis with nasal polyps (CRSwNP). Dr. Rohit Katial joins Kortney and Dr. G to unpack what CRSwNP really is, how it develops, and why type 2 inflammation plays such a key role. Together, they explain what's happening inside the sinuses, what symptoms to look for, and when it's time to see a specialist. What we cover about CRSwNP: What CRSwNP means: Chronic rhinosinusitis with nasal polyps is long-term inflammation of the nose and sinuses that lasts 12 weeks or more. What nasal polyps are: Soft, fluid-filled sacs (often “grape” or “pea” sized) that block airflow and lead to congestion and smell loss. Why it happens: Type 2 inflammation drives CRSwNP. Immune messengers like IL-4, IL-5, and IL-13 cause swelling and fluid buildup in the nasal lining. Who it affects: CRSwNP often overlaps with asthma, allergies, or aspirin sensitivity (AERD or Samter's Triad), making symptoms worse. When to seek help: If congestion, pressure, or loss of smell lasts more than 12 weeks, see an allergist or an ENT specialist. Early care can prevent sinus damage and improve breathing and quality of life. More episodes to support CRSwNP Ep. 101: What is Type 2 Inflammation? Ep. 102: Comorbidities of Type 2 Inflammation - Connecting the Dots Between Multiple Allergic Conditions Ep. 109: Tezepelumab & Nasal Polyps - Inside the WAYPOINT Phase III Trial ___ Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.
Description: Listen as NPF Medical Board Members, dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman discuss the connections between psoriasis and psoriatic arthritis, from cytokines to triggers, current and future treatments. Join moderator Alan Simmons as he gains insights on what connects psoriasis and psoriatic arthritis with leading experts in psoriatic disease and NPF Medical Board members, dermatologist Dr. Robert Kalb with Buffalo Medical Group Dermatology, and rheumatologist Dr. Sergio Schwartzman from Schwartzman Rheumatology, as they discuss the known drivers of psoriasis and psoriatic arthritis, common triggers, benefits of targeted treatments, remission of disease, and upcoming treatment trends. The intent of this episode is to identify potential connections between psoriasis and psoriatic arthritis, and how targeted treatments have changed the outlook for management of psoriatic disease. This episode is sponsored by Novartis. Timestamps: (0:41) Intro to Psoriasis Uncovered and guest welcome dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman who are both involved in clinical care and research of psoriasis and psoriatic arthritis. (1:15) Current known pro-inflammatory cytokines and cells found in psoriasis and psoriatic arthritis. (5:33) Types of psoriasis that may lead to a higher risk of developing psoriatic arthritis. (9:33) Common triggers for psoriasis and psoriatic arthritis that could cause flares of the disease. (12:59) Key factors that are considered when choosing a treatment plan for any individual with psoriatic arthritis and psoriasis. (18:04) What treatment remission means for psoriasis. (19:36) Use of minimal disease activity (MDA) in psoriatic arthritis and what it means. (22:14) How a better understanding of the disease has led to more effective treatment choices and what choices are used by Dr. Kalb and Dr. Schwartzman for the management of psoriasis and psoriatic arthritis. (28:39) New developments in treatment and research in psoriatic arthritis and psoriasis. (36:01) Given treatment advancements it's a wonderful time to treat psoriatic disease. 3 Key Takeaways: · Cytokines are chemicals in the body that moderate various processes. In psoriasis and psoriatic arthritis, an unknown trigger stimulates some cells to overproduce pro-inflammatory cytokines such as TNF-alpha, IL-17 or IL-23 leading to the development of skin and joint disease. · Treating psoriasis and psoriatic arthritis helps move the body towards normalizing the over reactive immune system especially with more targeted treatments that safely and effectively block specific cytokines without affecting other organ systems. · Given advancements in targeted treatments the goal is to reach and maintain remission of psoriatic disease. Guest Bios: Leading dermatologist Robert Kalb, M.D. is the Chair of the Buffalo Medical Group Dermatology Department and the Director of the Buffalo Medical Group Phototherapy Center, one of the leading centers for psoriasis care in Western New York. He is also a Clinical Professor of Dermatology at the State University of New York at Buffalo School of Medicine and Biomedical Sciences (SUNY Buffalo), as well as an Adjunct Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania where he plays a significant role in medical education, mentoring both medical students and dermatology residents. Dr. Kalb has extensive experience managing psoriasis, atopic dermatitis, and other inflammatory skin diseases. He has authored 70+ publications and is actively involved in clinical research, particularly focused on new treatment options for psoriasis. He is a member of the NPF Medical Board, American Academy of Dermatology, and is a member of the International Psoriasis Council. Sergio Schwartzman, MD, is a world-renowned rheumatologist based in New York City who brings almost 40 years of experience and personalized clinical care for those who have psoriatic disease. Along with being in private practice at Schwartzman Rheumatology, Dr. Schwartzman is a Clinical Associate Professor of Medicine at Weill Cornell Medical College of Cornell University, the New York-Presbyterian Hospital, and the Hospital for Special Surgery in New York City where he has played a role in educating medical students, residents, fellows, and peers in rheumatology. Additionally, Dr. Schwartzman is the emeritus Franchellie M. Cadwell Clinical Associate Professor at the Hospital for Special Surgery. Dr. Schwartzman's current research interests include psoriatic arthritis, the spondyloarthritis group of diseases, ankylosing spondylitis, rheumatoid arthritis, as well as defining and treating autoimmune diseases of the eye. He has authored, co-authored, and edited over 150 papers, abstracts, books and book chapters on topics including psoriatic arthritis, ankylosing spondylitis, axial spondylarthritis, rheumatoid arthritis, lupus, autoimmune eye disorders, and other rheumatological and autoimmune conditions. He is a member of the NPF Medical Board. He is also a member of the American College of Rheumatology, the Association for Research in Vision and Ophthalmology, the Spondyloarthritis Research and Treatment Network (SPARTAN), the American Uveitis Society, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Resources: Ø “Redefining Remission. A new definition for patients, providers, and payers.” Advance Online, National Psoriasis Foundation. S. Schlosser. July 14, 2025. Ø Treatment and Management of Psoriasis Ø Treatment and Management of Psoriatic Arthritis
Summary In this truncated replay, Dr. Shyam Joshi explores the intersection between allergy and dermatology—focusing on how chronic spontaneous urticaria (CSU), atopic dermatitis, and food allergies often overlap. Learn how emerging biologics like omalizumab and dupilumab are reshaping treatment decisions, why comorbidities matter, and how collaboration between allergists and dermatologists creates better outcomes for patients with complex allergic and dermatologic conditions. This episode dives into real-world case studies, FDA updates on antihistamines, and the multidisciplinary approach to managing eczema and CSU in pediatric and adult populations. Takeaways - FDA Advisory on Antihistamines: Long-term use of cetirizine or levocetirizine can lead to rebound pruritus upon discontinuation—but gradual tapering minimizes symptoms. - Biologic Selection Depends on Comorbidities: - Omalizumab is effective for IgE-mediated food allergies and chronic urticaria. - Dupilumab is preferred for patients with eosinophilic esophagitis (EoE) or moderate-to-severe atopic dermatitis. - CSU Is Systemic: Symptoms may extend beyond hives—impacting joints, sleep, and energy levels. - Comorbid Conditions Are Common: Up to 20 % of CSU patients have asthma, allergic rhinitis, or food allergies; identifying these helps guide treatment and patient education. - Unified Messaging Builds Trust: Consistent communication from both dermatologists and allergists reduces unnecessary testing and supports adherence to treatment plans. Chapters 00:00 - Introduction: Bridging Allergy and Dermatology 00:45 - Case Study: An 18-Year-Old with Chronic Urticaria 02:00 - FDA Warning: Antihistamine Withdrawal Itch 03:45 - Selecting the Right Biologic: Food Allergy Considerations 04:45 - Eosinophilic Esophagitis and CSU 05:35 - The Systemic Nature of CSU 06:40 - Comorbidities in CSU and Atopic Patients 07:30 - Multidisciplinary Collaboration in Practice 08:00 - Closing Thoughts & Educational Disclaimer
In this episode of Derms and Conditions, host James Q. Del Rosso, DO, is joined by Natasha Mesinkovska, MD, associate professor of Dermatology at UC Irvine, to discuss the multifaceted challenges of alopecia areata (AA), an autoimmune condition with complex comorbidities and broad psychosocial implications. The conversation begins with the stigma of hair loss and the importance of addressing the patient's emotional well-being. Dr Mesinkovska highlights her approach: asking simple but direct questions about how patients are coping and connecting them with mental health resources when needed. Comorbidities and workup are also addressed, with Dr Mesinkovska sharing her pragmatic approach to labs: thyroid-stimulating hormone test as a baseline, selective additional testing for patients with indicators of comorbidities, and requesting consultation with endocrinology when indicated. Prognosis is also discussed, with childhood onset and family history noted as adverse factors. They next explore treatment expectations, beginning with the typical timeline of response seen with oral JAK inhibitors and the importance of allowing several months for optimal hair regrowth. Many patients, once regrowth occurs, ask when they can stop therapy in hopes that results will persist without ongoing treatment; this is an important moment to counsel patients on the chronic nature of AA and emphasize that discontinuing therapy often leads to renewed hair loss. Continuing oral JAK inhibitor therapy offers the greatest likelihood of maintaining regrowth over time. They review clinical data on the durability of response of the JAK inhibitors for AA, which has shown that relapse of hair loss is common once treatment is discontinued. For those who elect to stop therapy, it is essential to emphasize the need to resume treatment promptly at the first signs of relapse, under supervision of their dermatologist. Ongoing clinical and laboratory monitoring is also highlighted as critical to ensure long-term safety. Dr Mesinkovska then discusses differential diagnoses for AA, covering lichen planopilaris, trichotillomania, and other mimickers, with biopsy reserved for challenging cases. She next reviews the 3 approved JAK inhibitors for AA, baricitinib, ritlecitinib, and deuruxolitinib, highlighting differences in efficacy, dosing, speed of response, and the role of CYP2C9 testing specific to deuruxolitinib. Clinical study data are used to outline the features that distinguish deuruxolitinib, the newest oral JAK inhibitor, from the other agents. These include a potentially faster onset of hair regrowth, enhanced efficacy with twice-daily dosing, and the ability to identify individuals who metabolize the drug more slowly through CYP2C9 testing. Tune in to the full episode to hear how dermatologists can assess comorbidities, select systemic therapies, manage patient expectations, and support the psychosocial needs of those with AA to achieve more comprehensive care.
Today's guests are Amy Kratochvil, RHIT, CDIP, CCDS, system director for HIM coding and CDI at UChicago Medicine in Chicago, Illinois, and Tiara Minor, RN, BSN, CCDS, director of CDI at the University of Miami Health System in Miami, Florida. Today's show is hosted by ACDIS Director Rebecca Hendren and is part of our occasional series with members of the ACDIS Advisory Board. You can read more about today's guests, and the rest of the ACDIS Advisory Board here: https://acdis.org/membership/boards During the episode, Amy and Tiara mentioned several resources, which can be found at the links below: HCUP website for Elixhauser resources: https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp Actual comorbidity listing: https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/CMR-Reference-File-v2025-1.xlsx U.S. News & World Report methodology for Best Hospitals specialty rankings: https://health.usnews.com/media/best-hospitals/2025-2026_best_hospitals_specialty_rankings_methodology More info about the Best Hospital rankings, including an overview: https://www.usnews.com/info/blogs/press-room/articles/2025-07-29/u-s-news-announces-2025-2026-best-hospitals Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at info@acdis.org. Want to submit a question for a future "listener questions" episode? Fill out this brief form! CEU info: Each ACDIS Podcast episode now offers 0.5 ACDIS CEU which can be used toward recertifying your CCDS or CCDS-O credential for those who listen to the show in the first four days from the time of publication. To receive your 0.5 CEU, go to the show page on acdis.org, by clicking on the “ACDIS Podcast” link located under the “Free Resources” tab. To take the evaluation, click the most recent episode from the list on the podcast homepage, view the podcast recording at the bottom of that show page, and click the live link at the very end after the music has ended. Your certificate will be automatically emailed to you upon submitting the brief evaluation. (Note: If you are listening via a podcast app, click this link to go directly to the show page on acdis.org: https://acdis.org/acdis-podcast/advisory-board-series-elixhauser-comorbidities) Note: To ensure your certificate reaches you and does not get trapped in your organization's spam filters, please use a personal email address when completing the CEU evaluation form. The cut-off for today's episode CEU is Sunday, August 31, 2025, at 11:00 p.m. Eastern. After that point, the CEU period will close, and you will not be eligible for the 0.5 CEU for this week's episode. ACDIS update: Apply to join the ACDIS CDI Leadership Council for the 2025/2026 term by August 31! (https://www.surveymonkey.com/r/2025-2026-Council-application) Download all the CDI Week 2025 materials, including the official poster, fact sheet, and activity suggestions today! (https://bit.ly/40Qp5CQ) Subscribe to CDI Strategies, ACDIS' free weekly eNewsletter, to stay in the loop about all things CDI and ACDIS! (https://acdis.org/sign-cdi-strategies)
Dr. Robert Silverman, author of "Immune Reboot: Maximizing Immunity, Restoring Gut Health, and Optimizing Vitality," provides a comprehensive primer on the immune system. He explains how lifestyle factors—diet, sleep, exercise, and stress—impact immune resilience. He offers specific protocols for optimizing resistance to Covid, what to do if you come down with it, and how to treat Long Covid, as well as how to prepare for vaccines.
Dr. Hoffman continues his conversation with Dr. Robert Silverman, author of "Immune Reboot: Maximizing Immunity, Restoring Gut Health, and Optimizing Vitality."
Concerned about screen time—both your kids' and your own? Perhaps you're navigating the decision of when to give your child a phone, or maybe you're rethinking past choices. While we all strive for improvement in managing screen time, our aim isn't to condemn technology or advocate for device-free living.Today, we welcome Dr. Ryan Sultan, an internationally recognized, double board-certified psychiatrist who directs the Sultan Mental Health Informatics and Adaptation Lab at Columbia University. Dr. Sultan offers expert guidance on discussing algorithms and short-form content with your children, fostering independent thinking. We'll also delve into the spread of misinformation and reactionary content, as well as the correlation between screen time and depression. Tune in for his practical advice on immediate steps you can take to help your kids gain better control over their screen time, even if they're already knee deep.(00:00:58) Welcome Dr. Ryan Sultan to the podcast.(00:04:25) If you only get one thing out of this conversation, THIS is it.(00:09:28) What is actually happening in the brain when we're using our phones? (00:15:27) Talking to our kids about algorithms.(00:21:20) When to introduce screens to kids and what age to give a phone.(00:26:16) Neurodivergence and devices: a higher risk group.(00:30:12) Heavy social media use and depression, anxiety,and suicidal ideation.(00:33:31) Multiplayer video games: are they social media?(00:36:10) Setting boundaries: a medium between doing nothing and taking it all away.(00:43:28) Sultan Lab Big Data for social media and mental health guidelines.(00:48:18) Parents, we need regulation and it's NOT impossible.(00:53:42) Summary and what to implement in your household right now to get better control over screen time.(00:56:00) Where to find Dr. Ryan Sultan. Integrative Psychiatry is a psychiatry practice that takes a holistic, collaborative approach to mental health care. The Columbia-trained clinical team provides expert, evidence-based treatment for ADHD, anxiety, depression, substance use, eating disorders, and other mental health conditions. The clinicians combine psychotherapy, research-supported psychotropic medications, and expertise as adult, adolescent, and child psychiatrists to deliver patient-centered care that meets each individual's unique needs—supporting long-term mental well-being and overall wellness.The practice is led by Dr. Ryan Sultan, an internationally recognized, double board-certified psychiatrist. He also serves as an Assistant Professor of Clinical Psychiatry at Columbia University, where he leads the Sultan Mental Health Informatics and Adaptation Lab.To learn more, visit Integrative Psychiatry or Sultan Lab. References:Sultan, R. S. (2017). Off-Label Prescribing of Antipsychotics for Youths: Who Should Be Treated? Psychiatric Times, 34(9), 26.Sultan, R. S., Liu, S. M., Hacker, K. A., & Olfson, M. (2021). Adolescents with Attention-Deficit/Hyperactivity Disorder: Adverse Behaviors and Comorbidity. Journal of Adolescent Health, 68(2), 284-291.Sultan, R. S., Saunders, D. C., & Veenstra-VanderWeele, J. (2025). Protective Effects of ADHD Medication on Real-World Outcomes. JAMA Psychiatry.Want to leave the TTSL Podcast a voicemail? We love your questions and adore hearing from you. https://www.speakpipe.com/TheThickThighsSaveLivesPodcastThe CVG Nation app, for iPhoneThe CVG Nation app, for AndroidOur Fitness FB Group.Thick Thighs Save Lives Workout ProgramsConstantly Varied Gear's Workout Leggings
Are you unknowingly damaging your brain and raising your cancer risk with just one drink? Discover the alarming truth about alcohol from Dr. Sarah Wakeman, what every adult needs to know now. Dr. Sarah Wakeman is a senior medical director for substance use disorder at Massachusetts General Brigham Hospital, the number one research hospital in the world. She is also the Medical Director of the Mass General Hospital Addiction Consult Team and Assistant Professor of Medicine at Harvard Medical School. She explains: How alcohol is hijacking your dopamine system. Why no amount of alcohol is good for your brain. The shocking truth about moderate drinking. How doctors are failing addiction patients on a daily basis. Why 1 in 3 people will struggle with alcohol. 00:00 Intro 02:23 Sarah's Mission 02:52 Sarah's Education and Experience 03:40 Issues With Addiction Treatment in the Modern World 04:31 What Is Addiction? 05:48 What Things Are Capable of Being Addictive? 06:47 Physiological Dependence vs. Addiction 07:25 Scale of the Problem: Why Should People Care? 08:59 Is Society Getting Better or More Addicted? 09:32 Substance-Related Deaths During the Pandemic 10:22 What Drives People to Use Substances? 12:24 Substances' Effects on the Brain 14:29 Does Trauma at a Young Age Increase Addiction Risk? 16:36 The Opposite of Addiction Is Connection 18:11 Why Addiction Matters to Sarah 19:02 Living With a Family Member Struggling With Addiction 20:43 Who Is Sarah Trying to Save? 22:57 Change Happens When the Pain of Staying the Same Is Greater Than the Pain of Change 25:53 Misconceptions About Alcohol 28:15 Is There a Healthy Level of Alcohol Consumption? 28:50 Is One Drink a Day Safe for Health? 30:38 Link Between Moderate Drinking and Cancer 33:23 Types of Cancer Linked to Alcohol Consumption 34:51 Cancer Risk Among Heavy Drinkers 35:31 Heavy Drinking and Comorbidities as Cancer Risk Factors 36:20 How Alcohol Drives Cancer Mechanisms 38:00 Alcohol and Weight Gain 38:54 The Role of the Liver 42:07 Liver's Ability to Regenerate 46:37 How Alcohol Causes Brain Deterioration 47:23 Other Organs Affected by Alcohol 48:00 Alcohol's Impact on the Heart 49:08 Body Fat Percentage and Alcohol Tolerance 50:05 Does High Alcohol Tolerance Prevent Organ Damage? 50:46 What Is a Hangover? 52:14 Balancing the Risks and Benefits of Alcohol 53:47 Is Rehab Effective for Addiction? 56:50 Psychedelic Therapy for Addiction 57:36 GLP-1 Medications for Addiction Treatment 59:03 Ads 59:59 Celebrity Addictions 1:02:24 Stigma Around Addiction 1:04:41 Addiction Cases That Broke Sarah's Heart 1:12:43 Is Empathy Positive Reinforcement for Addicted Individuals? 1:15:34 Setting Boundaries With an Addicted Person 1:18:57 Motivational Interviewing to Support Recovery 1:22:19 Finding Motivation for Positive Change 1:26:03 Habits to Support Addiction Recovery 1:29:12 Ads 1:30:18 Can the Brain Recover From Addiction? 1:34:55 Unexpected Sources of Addictive Behavior 1:35:35 How Sarah Copes With Difficult Addiction Cases 1:37:10 Importance of Language Around Addiction 1:41:40 How Labels Limit People's Potential 1:46:05 Sarah's Upcoming Book You can find out more about Dr. Sarah's profile, here: https://bit.ly/4mxu191 Ready to think like a CEO? Gain access to the 100 CEOs newsletter here: bit.ly/100-ceos-megaphone The 1% Diary is back - limited time only: https://bit.ly/3YFbJbt The Diary Of A CEO Conversation Cards (Second Edition): https://g2ul0.app.link/f31dsUttKKb Get email updates: https://bit.ly/diary-of-a-ceo-yt Follow Steven: https://g2ul0.app.link/gnGqL4IsKKb Research document: https://drive.google.com/file/d/11xEfVt4S6nFyJw8jTJNysBPVUra2CzWK/view?usp=sharing Sponsors: Ekster - https://partner.ekster.com/DIARYOFACEO with code DOACLinkedin Ads - https://www.linkedin.com/DIARY Learn more about your ad choices. Visit megaphone.fm/adchoices
© 2020-2026 Ivy Podcast Discovery LLC
